Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS-2032
- Development stage
- Approved
- Lead developer
- CanSino Biologics
- Modality
- Vaccines & Immunotherapeutics, Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular, Inhalation
01
Overview
CS-2032 is a recombinant zoster (shingles) vaccine developed by CanSino Biologics Inc. in collaboration with Vaccitech. It utilizes chimpanzee adenovirus vector (ChAdOx1 Vector technology) to deliver antigens of the varicella-zoster virus, thereby stimulating both cellular and humoral immunity. The vaccine is intended for adults over 50 to prevent skin shingles and neuralgia caused by the varicella-zoster virus. Pre-clinical research data suggests that CS-2032 elicits a significantly higher systemic cellular response compared to Shingrix, another recombinant zoster vaccine. No animal-derived ingredients are used in its production.
- Brand names
- Shingrix
- Other names
- Recombinant Zoster Vaccine (Adenovirus Vector)CS-2032 Zoster VaccineCS2032 Zoster VaccineCS 2032 Zoster Vaccinerecombinant adenovirus-vectored zoster vaccine
02
Targets
gE (VZV glycoprotein E)
Beyond the preview
Go deeper on CS-2032.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CS-2032.